Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 16:8:681172.
doi: 10.3389/fmed.2021.681172. eCollection 2021.

Psoriasis to Psoriatic Arthritis: The Application of Proteomics Technologies

Fei Qi  1 , Yaqi Tan  1 , Amin Yao  1 , Xutong Yang  1 , Yanling He  1
Affiliations
Review

Psoriasis to Psoriatic Arthritis: The Application of Proteomics Technologies

Fei Qi et al. Front Med (Lausanne). .

Abstract

Psoriatic disease (PsD) is a spectrum of diseases that affect both skin [cutaneous psoriasis (PsC)] and musculoskeletal features [psoriatic arthritis (PsA)]. A considerable number of patients with PsC have asymptomatic synovio-entheseal inflammations, and approximately one-third of those eventually progress to PsA with an enigmatic mechanism. Published studies have shown that early interventions to the very early-stage PsA would effectively prevent substantial bone destructions or deformities, suggesting an unmet goal for exploring early PsA biomarkers. The emergence of proteomics technologies brings a complete view of all involved proteins in PsA transitions, offers a unique chance to map all potential peptides, and allows a direct head-to-head comparison of interaction pathways in PsC and PsA. This review summarized the latest development of proteomics technologies, highlighted its application in PsA biomarker discovery, and discussed the possible clinical detectable PsA risk factors in patients with PsC.

Keywords: biomarkers; proteomics; psoriasis; psoriatic arthritis; psoriatic disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Overview of the potential biomarkers of PsA found through proteomic technologies from four different kinds of biological samples: Biomarkers from synovial fluid and skin tissues are presented in the figure. No possible biomarkers are found from urine and serum. PsA, psoriatic arthritis; PEA, proximity extension assay.
See this image and copyright information in PMC

References

    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. (2020) 323:1945–60. 10.1001/jama.2020.4006 - DOI - PubMed
    1. Jadon DR, Stober C, Pennington SR, Fitzgerald O. Applying precision medicine to unmet clinical needs in psoriatic disease. Nat Rev Rheumatol. (2020) 16:609–27. 10.1038/s41584-020-00507-9 - DOI - PubMed
    1. Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, et al. . Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol. (2015) 67:934–44. 10.1002/art.38995 - DOI - PMC - PubMed
    1. Pollock RA, Abji F, Liang K, Chandran V, Pellett FJ, Virtanen C, et al. . Gene expression differences between psoriasis patients with and without inflammatory arthritis. J Invest Dermatol. (2015) 135:620–3. 10.1038/jid.2014.414 - DOI - PubMed
    1. Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, et al. . Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. (2015) 97:816–36. 10.1016/j.ajhg.2015.10.019 - DOI - PMC - PubMed